膀胱肿瘤经尿道等离子电切术临床路径释义

Interpretation of the clinical pathway for transurethral plasmakinetic resection of bladder tumor

膀胱癌是全球第十大最常被诊断出的癌症,在男性中更常见。经尿道膀胱肿瘤电切术既是膀胱肿瘤的重要诊断方法,也是非肌层浸润性膀胱癌的主要治疗手段。相较于传统单极电切,等离子双极电切具有手术效果好、并发症较少的优势,临床应用渐趋广泛。为规范常见病的诊疗,国家卫健委持续发布相关的临床路径,但临床路径的内容有限,对其进行释义可以更好的推广使用。本释义以最新发布的《膀胱肿瘤经尿道等离子电切术临床路径(2019年版)》为蓝本,采用循证医学的方法,对路径中涉及的给药方案进行了详细解读,以期为医护及管理人员能够更好地理解、把握和正确运用临床路径提供参考。

Bladder cancer is the tenth most frequently diagnosed cancer in the world, and is more common among men. Transurethral resection of bladder tumor is not only an important diagnostic method for bladder tumors, but also a major treatment for nonmuscle invasive bladder cancer. Compared with traditional unipolar electrotomy, plasma bipolar electrotomy has the advantages of good surgical results and fewer complications,and its clinical application is becoming more and more extensive. In order to standardize the diagnosis and treatment of common diseases, the National Health Commission continues to issue relevant clinical pathways;however, the content of a clinical pathway is limited, and its interpretation can help it be better disseminated and used. This interpretation is based on the latest "clinical pathway for transurethral plasma resection of bladder tumor(2019 edition)". It uses the method of evidence-based medicine to make a detailed and necessary supplementary description of the pathway, and gives a detailed interpretation of the drug delivery scheme involved, so as to provide reference for medical staff and managers to better understand, grasp and correctly use it.